Resolve Therapeutics Receives FDA Approval to Initiate Phase 2 Clinical Trial of RSLV-132 in Long Covid Patients

ST. PETERSBURG, Fla., June 23, 2021 /PRNewswire/ -- Resolve Therapeutics, pioneering first-in-class, targeted, safe therapies for underserved autoimmune diseases, today announced that the US Food and Drug Administration has approved a...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials